Alvotech vs Travere Therapeutics
Alvotech is the larger business, with $586m of revenue in fiscal 2025 against $491m for Travere Therapeutics (1.2 times as much). Travere Therapeutics grew faster (110.5% against 19.7%). Alvotech kept more of each dollar of sales as profit: a net margin of 4.8% against -5.2%.
| Latest fiscal year | AlvotechALVO, 2025 | Travere TherapeuticsTVTX, 2025 |
|---|---|---|
| Revenue | $586m | $491m |
| Revenue growth | 19.7% | 110.5% |
| Net income | $27.9m | −$25.5m |
| Operating margin | 13.3% | — |
| Net margin | 4.8% | -5.2% |
| Return on equity | — | -29.4% |
| Free cash flow | −$115m | $37.8m |
| Cash | $172m | $93.0m |
| Total debt | $1.30bn | $312m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 497 |
| Market value | $1.42bn | $4.63bn |
| Price vs our value range | — | — |
| Moat score | — | 36 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 119 sales |